Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michelle Weiss

Allergy York, PA Medical Doctor

NPI 1366448409 CMS profile 16809

2605 Joppa Rd, York, PA 17403

Open in the dashboard

General payments

$7,476

416 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Weiss of York, PA is reported in the CMS Open Payments database as having received $7,476 across 416 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,062 49
2024 General $1,008 52
2023 General $1,268 66
2022 General $1,169 73
2021 General $1,076 65
2020 General $1,005 55
2019 General $889 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Weiss
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Michelle Weiss were reported at $1,062. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Michelle Weiss Allergy median Middle half National median
2019 $889 $506 $151–$1,337 $163
2020 $1,005 $409 $108–$1,162 $114
2021 $1,076 $549 $125–$1,485 $132
2022 $1,169 $666 $161–$1,594 $149
2023 $1,268 $780 $186–$1,916 $160
2024 $1,008 $1,031 $271–$2,196 $164
2025 $1,062 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,473 119 payments
  2. GlaxoSmithKline, LLC. $1,517 109 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $652 33 payments
  4. Novartis Pharmaceuticals Corporation $497 27 payments
  5. Pfizer Inc. $431 26 payments
  6. Regeneron Healthcare Solutions, Inc. $430 24 payments
  7. CSL Behring $217 12 payments
  8. OptiNose US, Inc. $194 10 payments
  9. kaleo, Inc. $165 9 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $148 6 payments
  11. Other $753 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,388 412 payments
  2. Education $88 4 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE $782 21 payments
  2. FASENRA Respiratory $768 22 payments
  3. NUCALA $693 56 payments
  4. TRELEGY ELLIPTA $682 42 payments
  5. AIRSUPRA $642 20 payments
  6. SPIRIVA RESPIMAT $477 28 payments
  7. EUCRISA $339 21 payments
  8. DUPIXENT $326 19 payments
  9. SYMBICORT $303 19 payments
  10. FASENRA Respiratory $287 17 payments
  11. Other $3,223 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

416 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record